Caribou Biosciences, Inc. (CRBU): Shareholders' Equity
$122.17M
As of 2025-12-31
$98.10M
As of 2026-06-30
-25.9%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $122.17M | -51.7% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $252.95M | -31.3% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $368.40M | +22.4% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $300.87M | -22.4% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $387.82M | n/m | 2023-03-09, Balance as of period end |
| 2020-12-31 | -$23.44M | n/m | 2022-03-21, Balance as of period end |
| 2019-12-31 | $7.46M | n/a | 2022-03-21, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $122.17M | -51.7% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $123.12M | -48.9% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $62.53M | +59.9% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $246.94M | +245.2% |
| Curis Inc (CRIS) | 2025-12-31 | $5.46M | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $43.35M | -43.7% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $567.06M | -27.1% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $38.88M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $207.18M | -35.0% |
Compare CRBU, TCRX, ACOG, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗